{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(4)"],"submitter":["Reynolds T"],"funding":["Sanofi"],"pubmed_abstract":["<h4>Background</h4>Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) and has been previously shown, in the phase III ODYSSEY clinical trial program, to provide significant lowering of low-density lipoprotein cholesterol (LDL-C) and reduction in risk of major adverse cardiovascular events. However, real-world evidence to date is limited.<h4>Objective</h4>The primary objective was to describe baseline characteristics, clinical history, and prior lipid-lowering therapy (LLT) use of patients initiated on alirocumab in UK clinical practice following publication of health technology appraisal (HTA) body recommendations. Secondary objectives included description of alirocumab use and lipid parameter outcomes over a 4-month follow-up period.<h"],"journal":["Drugs - real world outcomes"],"pagination":["205-213"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6879683"],"repository":["biostudies-literature"],"pubmed_title":["A Retrospective Observational Study to Determine Baseline Characteristics and Early Prescribing Patterns for Patients Receiving Alirocumab in UK Clinical Practice."],"pmcid":["PMC6879683"],"pubmed_authors":["George J","Reynolds T","Narayanan D","Ramachandran S","Carey P","Ferns G","Saunders L","Konidaris G","Viljoen A"],"additional_accession":[]},"is_claimable":false,"name":"A Retrospective Observational Study to Determine Baseline Characteristics and Early Prescribing Patterns for Patients Receiving Alirocumab in UK Clinical Practice.","description":"<h4>Background</h4>Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) and has been previously shown, in the phase III ODYSSEY clinical trial program, to provide significant lowering of low-density lipoprotein cholesterol (LDL-C) and reduction in risk of major adverse cardiovascular events. However, real-world evidence to date is limited.<h4>Objective</h4>The primary objective was to describe baseline characteristics, clinical history, and prior lipid-lowering therapy (LLT) use of patients initiated on alirocumab in UK clinical practice following publication of health technology appraisal (HTA) body recommendations. Secondary objectives included description of alirocumab use and lipid parameter outcomes over a 4-month follow-up period.<h","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Dec","modification":"2025-04-21T23:26:21.21Z","creation":"2020-05-21T21:22:43Z"},"accession":"S-EPMC6879683","cross_references":{"pubmed":["31741198"],"doi":["10.1007/s40801-019-00166-7"]}}